NUVALENT INC CLASS A (NUVL)
Health Care · Targeted oncology / precision medicine – tyrosine kinase inhibitors · NASDAQ
Nuvalent is a clinical-stage precision oncology company developing targeted kinase inhibitors to address the challenges of treatment resistance and off-target toxicities in cancer care.
What NUVALENT INC CLASS A does
Nuvalent is a clinical-stage biopharmaceutical company developing selective tyrosine kinase inhibitors (TKIs) for patients with specific oncogenic driver mutations in non-small cell lung cancer (NSCLC). The company's lead programs include zidesamtinib (NVL-520), a ROS1-selective inhibitor, and neladalkib (NVL-655), an ALK-selective inhibitor, both designed for TKI pre-treated advanced NSCLC. As of Q1 2026, Nuvalent had submitted an NDA for zidesamtinib with an FDA target action date of September 2026, and had just submitted an NDA for neladalkib; the company has not yet generated any revenue and has no approved products.
Themes: targeted oncology / precision cancer medicine, ROS1-positive NSCLC, ALK-positive NSCLC, HER2-selective inhibitors, TKI resistance / second-line therapy
Fundamentals
- Price$123.96 as of 2026-07-21 close
- Market cap$9.8B as of 2026-09-02
- 1-year return+50.3% 2025-07-21 close $82.46 → 2026-07-21 close $123.96
- P/En/a earnings data not available
- ROE-42.8% as of 2026-09-02
- Debt / equity0.00 as of 2026-09-02
- Beta0.90 as of 2026-09-02
- Last reported earnings2026-05-07 SEC EDGAR Form 8-K (Item 2.02)
How NUVL compares in its sector
- return on equitymiddle range 576 covered Health Care peers, as of 2026-09-02
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Analyst consensus
- Consensus ratingHold (3.00 mean, 1=Strong Buy…5=Strong Sell) — 9 analysts
- Mean price target$124.00 range $124.00 – $124.00
Analyst estimates, as of 2026-08-15. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for NUVL
- Consensus EPS estimate-$1.38 next reporting period, as of 2026-08-15
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Clinical-stage company with no approved products and no revenue; FDA approval is uncertain and the company has not demonstrated ability to successfully develop and commercialize products","Risk of delays or failure in NDA reviews: zidesamtinib has PDUFA target date of September 2026 and neladalkib NDA was just submitted; no assurance of approval by those dates or at all","Significant manufacturing, commercialization and capital requirements ahead; the company has limited operating history (commenced significant operations in 2018) and will need to transition from R&D-focused to commercial organization while requiring substantial additional funding"]
What changed in the latest 10-Q
AI-assisted comparison of NUVL's 10-Q filed 2026-05-07 against the prior one filed 2025-10-30.
Management's Discussion & Analysis (MD&A)
- Reworded:
- Reference to Form 10-K fiscal year changed from 'December 31, 2024, as filed with the SEC on February 27, 2025 (2024 Form 10-K)' in older filing to 'December 31, 2025, as filed with the SEC on February 26, 2026 (2025 Form 10-K)' in newer filing
- Notes:
- Both text excerpts are truncated and end mid-sentence at 'As a result of many factors, including those factors set forth in the "', preventing full comparison of the complete MD&A sections
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 9 open-market sales by insiders in the last 90 days.
- Last 90 days0 buys · 9 sells ($14M) — 4 selling insiders
- Last 180 days0 buys · 39 sells ($22M) — 5 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-07-09. As of 2026-09-02.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about NUVL's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Short interest (FINRA)
NUVL had 715,798 shares of reported short interest as of the 2026-07-15 FINRA settlement date (delayed, bi-monthly; not real-time).
Short interest as a percent of shares outstanding is not shown for NUVL because we do not hold a verified share count to divide it by. The reported figures above are unaffected.
- Reported short interest (shares) 715,798
- Prior settlement (shares) 2,908,403
- Reported change -75.39%
- Days to cover (reported) 1
Reported to FINRA as of the 2026-07-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Pfizer (PFE)
- Eli Lilly (LLY)
- Ariad Pharmaceuticals / Takeda Oncology
- Blueprint Medicines (BPMC)
- Ignyta (acquired by Genentech/Roche)
- Exelixis (EXEL)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare NUVL vs…
Frequently asked questions
What does NUVALENT INC CLASS A (NUVL) do?
Nuvalent is a clinical-stage biopharmaceutical company developing selective tyrosine kinase inhibitors (TKIs) for patients with specific oncogenic driver mutations in non-small cell lung cancer (NSCLC). The company's lead programs include zidesamtinib (NVL-520), a ROS1-selective inhibitor, and neladalkib (NVL-655), an ALK-selective inhibitor, both designed for TKI pre-treated advanced NSCLC.
What sector is NUVALENT INC CLASS A (NUVL) in?
NUVALENT INC CLASS A (NUVL) is classified in the Health Care sector. Its industry is Targeted oncology / precision medicine – tyrosine kinase inhibitors. It trades on NASDAQ.
Who are NUVALENT INC CLASS A's (NUVL) competitors?
Notable peers of NUVALENT INC CLASS A (NUVL) include Pfizer, Eli Lilly, Ariad Pharmaceuticals / Takeda Oncology, Blueprint Medicines and Ignyta (acquired by Genentech/Roche). This peer set is informational only — not financial advice.
Where does stocks-llm's data on NUVL come from?
Fundamentals and prices come from market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-09-02. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.